Cynosure Inc (CYNO) 51.59 $CYNO
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 117.43 (-0.20), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), ILMN: 167.90 (-0.66)
Edwards Lifesciences (EW) Tops Q2 Earnings, '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:39AM CDT
Edwards Lifesciences (EW) ended the second quarter on an encouraging note, with its financial numbers squarely beating the Zacks Consensus Estimate.
ABMD: 117.43 (-0.20), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), EW: 115.85 (-0.02)
Cynosure to Ring NASDAQ Stock Market Closing Bell to Celebrate 25 Year Anniversary
PR Newswire - Thu Jun 16, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that President and CEO Michael Davin, along with other members of the Company's management team, will ring the Closing Bell at the NASDAQ Stock Market on Wednesday, July 27, 2016 to celebrate its 25th anniversary. Cynosure was founded by the late Horace Furumoto, PhD, a pioneer in the field of aesthetic medicine.
CYNO: 51.59 (-0.36)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 4.23% Gain
Comtex SmarTrend(R) - Wed Jun 01, 4:25PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.93 to a high of $50.24. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $48.99 on volume of 385,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 51.59 (-0.36)
Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:44AM CDT
Cynosure Inc. (CYNO) recently announced the receipt of FDA approval for marketing a new Laser Delivery System (LDS) for PicoSure.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), EXAC: 27.90 (+0.10)
Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and Chief Operating Officer
PR Newswire - Wed May 25, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that Timothy W. Baker has notified the Company that he plans to retire to pursue philanthropic interests. Mr. Baker has served as Cynosure's President since 2014, as Chief Operating Officer since 2013, and as Chief Financial Officer since 2004. The Company has initiated a search for a CFO, and Mr. Baker plans to remain with Cynosure through the succession to help achieve a smooth transition. Michael R. Davin, the Company's Chairman and Chief Executive Officer, has been appointed President effective today.
CYNO: 51.59 (-0.36)
Cynosure Receives FDA Clearance to Market New PicoSure® Energy Delivery System for Tattoos and Pigmented Lesions
PR Newswire - Tue May 24, 7:30AM CDT
Broadening its product platform for tattoo removal and skin revitalization, Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received U.S. Food and Drug Administration 510(k) clearance to market a new Laser Delivery System for PicoSure®, the world's first aesthetic picosecond laser. Together with the FDA cleared 532 nm and 755 nm wavelengths, Cynosure's new 1064 nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks in fewer treatments.
CYNO: 51.59 (-0.36)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 6.74% Gain
Comtex SmarTrend(R) - Tue Apr 26, 4:12PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.11 to a high of $50.75. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $46.28 on volume of 867,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 51.59 (-0.36)
Cynosure tops Street 1Q forecasts
Automated Insights - Tue Apr 26, 7:28AM CDT
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported first-quarter net income of $2.8 million, after reporting a loss in the same period a year earlier.
CYNO: 51.59 (-0.36)
Cynosure To Host First-Quarter 2016 Financial Results Conference Call On April 26
PR Newswire - Mon Apr 18, 7:30AM CDT
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its first-quarter 2016 financial results before the market opens on Tuesday, April 26, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 51.59 (-0.36)
Cynosure Announces 20 Scientific Presentations at the American Society for Laser Medicine & Surgery's 36th Annual Conference
PR Newswire - Thu Mar 31, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that 17 scientific abstracts and three ePosters have been accepted for presentation at the 36th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS). The event is taking place today through April 3, 2016 at the Sheraton Boston Hotel & Hynes Convention Center in Boston, Massachusetts.
CYNO: 51.59 (-0.36)
Cynosure (CYNO) Up on Q4 Earnings and Revenue Beat
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:10AM CST
Shares of Cynosure (CYNO) rallied 4.2% ($1.43) to close at $35.20 on Feb 9, following the company's impressive fourth-quarter 2015 results.
ABMD: 117.43 (-0.20), CYNO: 51.59 (-0.36), EXAC: 27.90 (+0.10), LMNX: 21.12 (+0.19)
Cynosure beats Street 4Q forecasts
Automated Insights - Tue Feb 09, 7:21AM CST
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported fourth-quarter earnings of $7.2 million.
CYNO: 51.59 (-0.36)
Why Cynosure (CYNO) Might Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 7:35AM CST
Cynosure (CYNO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat
CYNO: 51.59 (-0.36)
Cynosure to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
PR Newswire - Thu Feb 04, 8:15AM CST
Cynosure, Inc. (NASDAQ: CYNO) today announced that Chairman and Chief Executive Officer Michael Davin and Tim Baker, the Company's President and Chief Financial Officer, will participate in the LEERINK Partners 5th Annual Global Healthcare Conference in New York City.
CYNO: 51.59 (-0.36)
Medical Aesthetics Market Forecast to 2020 - Increasing Demand For Minimally Invasive & Non-Invasive Aesthetic Procedures
M2 - Thu Jan 28, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bd5l42/medical) has announced the addition of the "Medical Aesthetics Market by Products, Procedures, & End-Users - Global Forecast to 2020" report to their offering. The market is expected to reach $12,581.9 Million by 2020, at a CAGR of 10.8% from 2015 to 2020. Factors such as the increasing demand of minimally invasive and non-invasive aesthetic procedures, technological advancements in energy based devices, and rapid growth in number of cosmetic procedures are driving the growth of the global medical aesthetics market. However, stringent safety regulations for aesthetic procedures, and a significant number of product recalls are restricting the growth of the global medical aesthetics market. Geographically, North America (comprising the U.S. and Canada) commanded the largest share of 49.0% of the global medical aesthetics market in 2015, followed by Europe. North America will continue to lead in the years to come, owing to rapidly aging and obese population, technological advancements, and growing FDA approvals of devices in the U.S. The growth of the global medical aesthetics market is mainly driven by the growing adoption of minimally invasive and noninvasive aesthetic procedures, aging population, increasing awareness among customers, technological advancements in energy-based devices, rising number of aesthetic procedures, and increasing demand for aesthetic treatments among the male population. However, a stringent safety regulation for aesthetic procedures is a major factor restraining the growth of this market. Growing adoption of home use aesthetic devices and increasing demand for cosmetic treatments in emerging markets are creating opportunities for growth of the medical aesthetics market. Companies Mentioned: - Allergan, Inc. - Cynosure, Inc. - Galderma S.A. (Switzerland) - Lumenis Ltd. - Mentor Worldwide LLC - PhotoMedex, Inc. - Solta Medical, Inc. - Syneron Medical, Ltd. - ZELTIQ Aesthetics, Inc. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Market, By Product 7 Medical Aesthetics Market, By End User 8 Medical Aesthetics Market, By Procedure 9 Global Medical Aesthetics Market, By Region 10 Competitive Landscape 11 Company Profiles For more information visit http://www.researchandmarkets.com/research/bd5l42/medical
ELOS: 6.52 (-0.08), AGN: 235.96 (-1.80), ZLTQ: 38.07 (-0.14), CYNO: 51.59 (-0.36), LMNS: 13.76 (+0.04), PHMD: 0.22 (-0.02)
Cynosure To Host Fourth-Quarter 2015 Financial Results Conference Call On February 9
PR Newswire - Tue Jan 26, 7:30AM CST
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its fourth-quarter 2015 financial results before the market opens on Tuesday, February 9, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 51.59 (-0.36)
BUYINS.NET: CYNO, DBC, RYJ, VFH, CDR, VAW Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Jan 22, 6:52AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of CYNOSURE INC (NASDAQ:CYNO), Powershares DB Commodity Index Tracking Fund (NYSE
BC), Guggenheim Raymond James SB-1 Equity ETF (NYSE:RYJ), Vanguard Financials Etf (NYSE:VFH), Cedar Realty Trust Inc (NYSE:CDR), Vanguard Materials ETF (NYSE:VAW) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
RYJ: 36.26 (+0.33), VFH: 50.85 (+0.29), DBC: 14.39 (+0.16), CYNO: 51.59 (-0.36), CDR: 7.64 (+0.09), VAW: 109.53 (+1.03)
CynoSure Brings the Speed of Light to Non-Invasive Body Contouring...Introducing SculpSure®
PR Newswire - Thu Jan 21, 8:32AM CST
If your clothes could talk, what would they say? Is that little black dress a little too little or are last year's go-to pants now relegated to the back of the closet? Everyone has at least one piece of clothing in their closet they look at longingly, hoping to wear someday. However even with a healthy diet and regular exercise, fat in certain areas, such as the abdomen and love handles, can be particularly difficult to eliminate. In fact, 89% of Americans report feeling bothered by excess weight on their bodies.1 But now there's SculpSure, a breakthrough technology that reduces stubborn fat in problem areas for a more slender, sculpted figure, in just 25 minutes.
CYNO: 51.59 (-0.36)
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 117.43 (-0.20), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), ILMN: 167.90 (-0.66)
Edwards Lifesciences (EW) Tops Q2 Earnings, '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:39AM CDT
Edwards Lifesciences (EW) ended the second quarter on an encouraging note, with its financial numbers squarely beating the Zacks Consensus Estimate.
ABMD: 117.43 (-0.20), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), EW: 115.85 (-0.02)
Cynosure to Ring NASDAQ Stock Market Closing Bell to Celebrate 25 Year Anniversary
PR Newswire - Thu Jun 16, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that President and CEO Michael Davin, along with other members of the Company's management team, will ring the Closing Bell at the NASDAQ Stock Market on Wednesday, July 27, 2016 to celebrate its 25th anniversary. Cynosure was founded by the late Horace Furumoto, PhD, a pioneer in the field of aesthetic medicine.
CYNO: 51.59 (-0.36)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 4.23% Gain
Comtex SmarTrend(R) - Wed Jun 01, 4:25PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.93 to a high of $50.24. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $48.99 on volume of 385,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 51.59 (-0.36)
Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:44AM CDT
Cynosure Inc. (CYNO) recently announced the receipt of FDA approval for marketing a new Laser Delivery System (LDS) for PicoSure.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), CYNO: 51.59 (-0.36), EXAC: 27.90 (+0.10)
Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and Chief Operating Officer
PR Newswire - Wed May 25, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that Timothy W. Baker has notified the Company that he plans to retire to pursue philanthropic interests. Mr. Baker has served as Cynosure's President since 2014, as Chief Operating Officer since 2013, and as Chief Financial Officer since 2004. The Company has initiated a search for a CFO, and Mr. Baker plans to remain with Cynosure through the succession to help achieve a smooth transition. Michael R. Davin, the Company's Chairman and Chief Executive Officer, has been appointed President effective today.
CYNO: 51.59 (-0.36)
Cynosure Receives FDA Clearance to Market New PicoSure® Energy Delivery System for Tattoos and Pigmented Lesions
PR Newswire - Tue May 24, 7:30AM CDT
Broadening its product platform for tattoo removal and skin revitalization, Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received U.S. Food and Drug Administration 510(k) clearance to market a new Laser Delivery System for PicoSure®, the world's first aesthetic picosecond laser. Together with the FDA cleared 532 nm and 755 nm wavelengths, Cynosure's new 1064 nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks in fewer treatments.
CYNO: 51.59 (-0.36)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 6.74% Gain
Comtex SmarTrend(R) - Tue Apr 26, 4:12PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.11 to a high of $50.75. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $46.28 on volume of 867,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 51.59 (-0.36)
Cynosure tops Street 1Q forecasts
Automated Insights - Tue Apr 26, 7:28AM CDT
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported first-quarter net income of $2.8 million, after reporting a loss in the same period a year earlier.
CYNO: 51.59 (-0.36)
Cynosure To Host First-Quarter 2016 Financial Results Conference Call On April 26
PR Newswire - Mon Apr 18, 7:30AM CDT
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its first-quarter 2016 financial results before the market opens on Tuesday, April 26, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 51.59 (-0.36)
Cynosure Announces 20 Scientific Presentations at the American Society for Laser Medicine & Surgery's 36th Annual Conference
PR Newswire - Thu Mar 31, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that 17 scientific abstracts and three ePosters have been accepted for presentation at the 36th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS). The event is taking place today through April 3, 2016 at the Sheraton Boston Hotel & Hynes Convention Center in Boston, Massachusetts.
CYNO: 51.59 (-0.36)
Cynosure (CYNO) Up on Q4 Earnings and Revenue Beat
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:10AM CST
Shares of Cynosure (CYNO) rallied 4.2% ($1.43) to close at $35.20 on Feb 9, following the company's impressive fourth-quarter 2015 results.
ABMD: 117.43 (-0.20), CYNO: 51.59 (-0.36), EXAC: 27.90 (+0.10), LMNX: 21.12 (+0.19)
Cynosure beats Street 4Q forecasts
Automated Insights - Tue Feb 09, 7:21AM CST
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported fourth-quarter earnings of $7.2 million.
CYNO: 51.59 (-0.36)
Why Cynosure (CYNO) Might Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 7:35AM CST
Cynosure (CYNO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat
CYNO: 51.59 (-0.36)
Cynosure to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
PR Newswire - Thu Feb 04, 8:15AM CST
Cynosure, Inc. (NASDAQ: CYNO) today announced that Chairman and Chief Executive Officer Michael Davin and Tim Baker, the Company's President and Chief Financial Officer, will participate in the LEERINK Partners 5th Annual Global Healthcare Conference in New York City.
CYNO: 51.59 (-0.36)
Medical Aesthetics Market Forecast to 2020 - Increasing Demand For Minimally Invasive & Non-Invasive Aesthetic Procedures
M2 - Thu Jan 28, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bd5l42/medical) has announced the addition of the "Medical Aesthetics Market by Products, Procedures, & End-Users - Global Forecast to 2020" report to their offering. The market is expected to reach $12,581.9 Million by 2020, at a CAGR of 10.8% from 2015 to 2020. Factors such as the increasing demand of minimally invasive and non-invasive aesthetic procedures, technological advancements in energy based devices, and rapid growth in number of cosmetic procedures are driving the growth of the global medical aesthetics market. However, stringent safety regulations for aesthetic procedures, and a significant number of product recalls are restricting the growth of the global medical aesthetics market. Geographically, North America (comprising the U.S. and Canada) commanded the largest share of 49.0% of the global medical aesthetics market in 2015, followed by Europe. North America will continue to lead in the years to come, owing to rapidly aging and obese population, technological advancements, and growing FDA approvals of devices in the U.S. The growth of the global medical aesthetics market is mainly driven by the growing adoption of minimally invasive and noninvasive aesthetic procedures, aging population, increasing awareness among customers, technological advancements in energy-based devices, rising number of aesthetic procedures, and increasing demand for aesthetic treatments among the male population. However, a stringent safety regulation for aesthetic procedures is a major factor restraining the growth of this market. Growing adoption of home use aesthetic devices and increasing demand for cosmetic treatments in emerging markets are creating opportunities for growth of the medical aesthetics market. Companies Mentioned: - Allergan, Inc. - Cynosure, Inc. - Galderma S.A. (Switzerland) - Lumenis Ltd. - Mentor Worldwide LLC - PhotoMedex, Inc. - Solta Medical, Inc. - Syneron Medical, Ltd. - ZELTIQ Aesthetics, Inc. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Market, By Product 7 Medical Aesthetics Market, By End User 8 Medical Aesthetics Market, By Procedure 9 Global Medical Aesthetics Market, By Region 10 Competitive Landscape 11 Company Profiles For more information visit http://www.researchandmarkets.com/research/bd5l42/medical
ELOS: 6.52 (-0.08), AGN: 235.96 (-1.80), ZLTQ: 38.07 (-0.14), CYNO: 51.59 (-0.36), LMNS: 13.76 (+0.04), PHMD: 0.22 (-0.02)
Cynosure To Host Fourth-Quarter 2015 Financial Results Conference Call On February 9
PR Newswire - Tue Jan 26, 7:30AM CST
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its fourth-quarter 2015 financial results before the market opens on Tuesday, February 9, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 51.59 (-0.36)
BUYINS.NET: CYNO, DBC, RYJ, VFH, CDR, VAW Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Jan 22, 6:52AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of CYNOSURE INC (NASDAQ:CYNO), Powershares DB Commodity Index Tracking Fund (NYSE
BC), Guggenheim Raymond James SB-1 Equity ETF (NYSE:RYJ), Vanguard Financials Etf (NYSE:VFH), Cedar Realty Trust Inc (NYSE:CDR), Vanguard Materials ETF (NYSE:VAW) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: RYJ: 36.26 (+0.33), VFH: 50.85 (+0.29), DBC: 14.39 (+0.16), CYNO: 51.59 (-0.36), CDR: 7.64 (+0.09), VAW: 109.53 (+1.03)
CynoSure Brings the Speed of Light to Non-Invasive Body Contouring...Introducing SculpSure®
PR Newswire - Thu Jan 21, 8:32AM CST
If your clothes could talk, what would they say? Is that little black dress a little too little or are last year's go-to pants now relegated to the back of the closet? Everyone has at least one piece of clothing in their closet they look at longingly, hoping to wear someday. However even with a healthy diet and regular exercise, fat in certain areas, such as the abdomen and love handles, can be particularly difficult to eliminate. In fact, 89% of Americans report feeling bothered by excess weight on their bodies.1 But now there's SculpSure, a breakthrough technology that reduces stubborn fat in problem areas for a more slender, sculpted figure, in just 25 minutes.
CYNO: 51.59 (-0.36)
